Design of Safe Nanotherapeutics for the Excretion of Excess Systemic Toxic Iron.

ABSTRACT: Chronic transfusion of red blood cells (RBCs) to patients with β-thalassemia, sickle cell disease, and other acquired anemic disorders generates significant amounts of bioactive iron deposits in the body. The inactivation and excretion of redox active iron(III) from the blood pool and organs are critical to prevent organ damage, and are the focus of iron chelation therapy (ICT) using low molecular weight Fe(III) specific chelators. However, the current ICT is suboptimal because of the short circulation time of chelators, toxicity, severe side effects, difficult regime of administration, and patient noncompliance. To address this issue, we have designed long circulating and biodegradable nanoconjugates with enhanced circulation time and well-defined biodegradability to improve iron excretio

SUBMITTER: Abbina S 

PROVIDER: S-EPMC6535967 | biostudies-literature | 2019 May

REPOSITORIES: biostudies-literature